当前位置： SCI文献检索 > CLINICAL DRUG INVESTIGATION期刊下所有文献 > Iobitridol: a review of its use as a contrast medium in diagnostic imaging.

Iobitridol: a review of its use as a contrast medium in diagnostic imaging.

Abstract：

:Iobitridol is a water-soluble, non-ionic, monomeric, low-osmolar, iodine-based contrast medium in which the potential for interaction with membrane proteins in the body has been minimized by stable masking of the molecule's lipophilic tri-iodinated benzene ring. It is approved in various countries worldwide for use as an intravascular contrast medium in adults and children. This article reviews the diagnostic efficacy and tolerability of iobitridol use as an intravascular contrast agent in diagnostic imaging, and briefly overviews its pharmacological properties. In randomized controlled trials, the global image quality and diagnostic quality with iobitridol did not differ from those with other low-osmolar contrast media (iohexol, iopromide, iopamidol, iomeprol and ioxaglate) or the iso-osmolar contrast medium iodixanol in adults or children undergoing radiographic imaging. Large post-marketing surveillance studies have confirmed that iobitridol produces good or excellent opacification and is an effective contrast agent in the vast majority of patients. Iobitridol was generally well tolerated and had a tolerability profile similar to that of other low-osmolar and iso-osmolar contrast media. Thus, iobitridol is an effective intravascular agent for contrast enhancement in diagnostic imaging.

journal_name

Clin Drug Investig

journal_title

Clinical drug investigation

authors

McCormack PL

doi

10.1007/s40261-013-0055-3

subject

Has Abstract

pub_date

2013-02-01 00:00:00

pages

155-66

issue

2

eissn

1173-2563

issn

1179-1918

journal_volume

33

pub_type

杂志文章,评审

相关文献

CLINICAL DRUG INVESTIGATION文献大全
  • CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.

    abstract：:Cytochrome P450 (CYP) 3A4 has been considered to be the most important enzyme system for metabolism of lopinavir/ritonavir (LPV/r), a widely used HIV protease inhibitor (PI) recommended during pregnancy. Herein we present a clinical case of a pregnant HIV-infected woman who was taking standard doses of LPV/r, 400/100 ...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-014-0245-7

    authors： López Aspiroz E,Cabrera Figueroa SE,Iglesias Gómez A,Valverde Merino MP,Domínguez-Gil Hurlé A

    更新日期：2015-01-01 00:00:00

  • Pharmacokinetic-pharmacodynamic relationship of dobutamine and heart rate, stroke volume and cardiac output in healthy volunteers.

    abstract：BACKGROUND AND OBJECTIVE:Dobutamine causes an increase in cardiac output (CO) by augmenting stroke volume (SV) through enhanced left ventricular contractility and by decreasing systemic vascular resistance. However, in some patients, the dominant mechanism by which dobutamine improves left ventricular performance is an...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,随机对照试验

    doi：10.2165/00044011-200828020-00006

    authors： Ahonen J,Aranko K,Iivanainen A,Maunuksela EL,Paloheimo M,Olkkola KT

    更新日期：2008-01-01 00:00:00

  • The Association between Polypharmacy and Hip Fracture in Osteoporotic Women: A Nested Case-Control Study in South Korea.

    abstract：BACKGROUND AND OBJECTIVE:Polypharmacy, regarded as an indicator of potentially inappropriate medications (PIMs), may lead to a higher risk of serious health consequences in elderly patients with osteoporosis. Thus, this study aimed to analyze the association between polypharmacy and hip fracture in patients with osteop...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-018-0716-3

    authors： Park HY,Kim S,Sohn HS,Kwon JW

    更新日期：2019-01-01 00:00:00

  • Severe INR elevation in a patient with choledocholithiasis receiving cefoperazone.

    abstract：:Cefoperazone is a third-generation cefalosporin that contains the N-methyl- thio-tetrazole (NMTT) side chain, which inhibits vitamin K-dependent carboxylation. Administration of NMTT-containing cefalosporins can cause alterations in the hepatic glutathione redox state, resulting in a dose-related increase in oxidised ...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.2165/00044011-200626080-00006

    authors： Alagozlu H,Cindoruk M,Unal S

    更新日期：2006-01-01 00:00:00

  • Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI.

    abstract：:We report the long-term effects of deferasirox 10-30 mg/kg/day on cardiac iron overload in a case series of five patients with transfusion-dependent beta-thalassaemia major who underwent up to 5 years of chelation therapy. Iron overload was monitored by multislice multi-echo T2* magnetic resonance imaging (MRI). Overa...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.2165/11534480-000000000-00000

    authors： Ruffo GB,Borsellino Z,Cuccia L,Marocco MR,Gagliardotto F,Tarantino R

    更新日期：2010-01-01 00:00:00

  • Pharmacokinetic Bioequivalence of Two Inhaled Tiotropium Bromide Formulations in Healthy Volunteers.

    abstract：BACKGROUND AND OBJECTIVE:A novel tiotropium bromide monodose capsule dry powder inhaler (DPI) formulation and device have been developed. The formulation was based on a spray-dried matrix that enhances the aerosolizaton properties, allowing a less active tiotropium metered dose (13 µg/capsule) while maintaining the sam...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s40261-016-0441-8

    authors： Algorta J,Andrade L,Medina M,Kirkov V,Arsova S,Li F,Chi J

    更新日期：2016-09-01 00:00:00

  • Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.

    abstract：BACKGROUND AND OBJECTIVES:Dyslipidaemia is a major cardiovascular risk factor associated with type 2 diabetes mellitus. Saroglitazar (ZYH1) is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity. It has been developed for the treatment of dyslipidaemia an...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s40261-013-0128-3

    authors： Jani RH,Kansagra K,Jain MR,Patel H

    更新日期：2013-11-01 00:00:00

  • Safety and tolerability of high-dose budesonide/formoterol via Turbuhaler® in Japanese patients with asthma: a randomized, double-blind, crossover, active comparator-controlled, phase III study.

    abstract：BACKGROUND:The use of budesonide/formoterol as both maintenance and reliever therapy in asthma is recommended in many countries; however, there are limited data available for the Asian patient population. OBJECTIVE:This study aimed to evaluate the short-term safety and tolerability of a fixed high-dose combination of ...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,随机对照试验

    doi：10.2165/11595440-000000000-00000

    authors： Saito T,Hasunuma T

    更新日期：2012-01-01 00:00:00

  • Pharmacokinetics, safety, and cardiovascular tolerability of phenylephrine HCl 10, 20, and 30 mg after a single oral administration in healthy volunteers.

    abstract：BACKGROUND AND OBJECTIVES:Phenylephrine HCl 10 mg has been used as a nasal decongestant for over 50 years, yet only limited pharmacokinetic and metabolic data are available. The purpose of this study was to evaluate single-dose pharmacokinetics and safety of phenylephrine HCl 10, 20, and 30 mg and to assess cardiovascu...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s40261-015-0311-9

    authors： Gelotte CK,Zimmerman BA

    更新日期：2015-09-01 00:00:00

  • Signals of Adverse Drug Reactions of Paliperidone Compared to Other Atypical Antipsychotics Using the Korean Adverse Event Reporting System Database.

    abstract：BACKGROUND AND OBJECTIVES:Schizophrenia is a severe public health problem and one of the top ten causes of disability, affecting about 1.1% of the world's population. Paliperidone is a new atypical antipsychotic used to treat schizophrenia. Several case reports about unexpected adverse drug reactions of paliperidone ha...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-020-00945-z

    authors： Seo DE,Kim S,Park BJ

    更新日期：2020-09-01 00:00:00

  • Manidipine for hypertension not controlled by dual therapy in patients with diabetes mellitus: a non-comparative, open-label study.

    abstract：BACKGROUND AND OBJECTIVE:Little is known about the effects of the calcium channel antagonist manidipine when it is added as a third drug in non-controlled hypertensive patients with diabetes mellitus receiving dual antihypertensive therapy. The aim of this study was to evaluate the response in terms of blood pressure (...

    journal_title：Clinical drug investigation

    pub_type： 临床试验,杂志文章

    doi：10.2165/11587400-000000000-00000

    authors： Martell-Claros N,de la Cruz JJ

    更新日期：2011-01-01 00:00:00

  • Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.

    abstract：BACKGROUND AND OBJECTIVES:Cancer pain affects patients at all stages of the disease and there are clear guidelines for its management. Morphine is considered the first-choice strong opioid in the treatment of moderate-to-severe pain; however, numerous studies have shown that oxycodone controlled-release (CR) has a simi...

    journal_title：Clinical drug investigation

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.2165/00044011-200828070-00001

    authors： Silvestri B,Bandieri E,Del Prete S,Ianniello GP,Micheletto G,Dambrosio M,Sabbatini G,Endrizzi L,Marra A,Aitini E,Calorio A,Garetto F,Nastasi G,Piantedosi F,Sidoti V,Spanu P

    更新日期：2008-01-01 00:00:00

  • Clinical experience with lamotrigine monotherapy in adults with newly diagnosed epilepsy: a review of published randomised clinical trials.

    abstract：OBJECTIVES:This paper aimed to provide an overview from published randomised clinical trials of the efficacy and tolerability of lamotrigine monotherapy compared with carbamazepine and phenytoin when initiated in adult patients with newly diagnosed epilepsy. DESIGN:The review included two double-blind, randomised tria...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.2165/00044011-199816020-00005

    authors： Mullens EL

    更新日期：1998-01-01 00:00:00

  • Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study.

    abstract：BACKGROUND AND OBJECTIVES:Fentanyl buccal soluble film (FBSF) is a small, bilayered, water-soluble polymer film (BioErodible MucoAdhesive; BEMA™) that adheres to the buccal mucosa and rapidly delivers fentanyl into the systemic circulation. It is approved for the treatment of cancer breakthrough pain in adult opioid-to...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.2165/11594670-000000000-00000

    authors： Finn AL,Vasisht N,Stark JG,Gever LN,Tagarro I

    更新日期：2012-01-01 00:00:00

  • High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease.

    abstract：OBJECTIVE:To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD). DESIGN AND PATIENTS:Randomised, double-blind, double-dummy, placebo-controlled study in 123 patients experiencing an acute exacerba...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.2165/00044011-200525060-00005

    authors： Zuin R,Palamidese A,Negrin R,Catozzo L,Scarda A,Balbinot M

    更新日期：2005-01-01 00:00:00

  • Observational Safety Study of Clottafact® Fibrinogen Concentrate: Real-World Data in Mexico.

    abstract：BACKGROUND AND OBJECTIVE:The use of fibrinogen concentrate to treat or prevent major bleeding with regard to potential adverse reactions has not been free of controversy. Our objective was to perform a post-authorization safety study to describe the use of Clottafact® (LFB Biomedicaments) fibrinogen concentrate in real...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-020-00906-6

    authors： Colin-Bracamontes I,Pérez-Calatayud ÁA,Carrillo-Esper R,Rodríguez-Ayala E,Padilla-Molina M,Posadas-Nava A,Olvera-Vázquez S,Hernández-Salgado L

    更新日期：2020-05-01 00:00:00

  • 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.

    abstract：:Intramuscular 17 α-hydroxyprogesterone caproate (Makena(®)), a synthetic progestin, is indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of a singleton spontaneous preterm birth. Makena(®) reduces the risk of preterm birth in this patient population, and is associated...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-013-0060-6

    authors： Hines M,Lyseng-Williamson KA,Deeks ED

    更新日期：2013-03-01 00:00:00

  • Proton pump inhibitors in acute treatment of reflux oesophagitis : a cost-effectiveness analysis.

    abstract：BACKGROUND AND AIM:Gastro-oesophageal reflux disease is a common medical problem that places a significant financial burden on outpatient pharmaceutical expenditure. A substantial proportion of this expenditure can be attributed to the use of proton pump inhibitors (PPIs). The aim of this analysis was to evaluate the c...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.2165/00044011-200525050-00005

    authors： Lucioni C,Mazzi S,Rossi C

    更新日期：2005-01-01 00:00:00

  • Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.

    abstract：BACKGROUND:Overactive bladder is a prevalent condition worldwide that is associated with a considerable burden, both on the patient and on society. OBJECTIVE:Our objective was to assess the economic value of fesoterodine compared with tolterodine extended release (ER) for the treatment of overactive bladder (OAB) with...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,评审

    doi：10.1007/s40261-014-0178-1

    authors： Angulo JC,Valpas A,Rejas J,Linden K,Kvasz M,Snedecor SJ

    更新日期：2014-05-01 00:00:00

  • Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.

    abstract：BACKGROUND AND OBJECTIVE:Several systematic reviews and meta-analyses have been conducted including an analysis to investigate the difference between ethnic groups in the glucose-lowering efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors. This study assessed the factors related to the glucose-lowering efficacy and ...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s40261-016-0478-8

    authors： Fujita K,Kaneko M,Narukawa M

    更新日期：2017-03-01 00:00:00

  • Lack of bioequivalence between two aciclovir tablets in healthy subjects.

    abstract：OBJECTIVE:This study aimed to compare the systemic bioavailability of two aciclovir tablets, Rouz-Aciclovir (test) and Zovirax (reference), in 12 healthy volunteers. METHODS:In a crossover design, each subject received a single oral dose of aciclovir 400 mg followed by a 7-day washout period. Plasma concentrations of ...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,随机对照试验

    doi：10.2165/00044011-200828010-00006

    authors： Amini H,Javan M,Gazerani P,Ghaffari A,Ahmadiani A

    更新日期：2008-01-01 00:00:00

  • US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection.

    abstract：:Elbasvir/grazoprevir demonstrated high sustained virologic response rates 12 weeks after the end of treatment (SVR12) across five clinical trials in subjects infected with chronic hepatitis C virus (HCV) genotype 1, including those with advanced chronic kidney disease (CKD), and GT4. Despite favorable results overall,...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-017-0492-5

    authors： Boyd SD,Tracy L,Komatsu TE,Harrington PR,Viswanathan P,Murray J,Sherwat A

    更新日期：2017-04-01 00:00:00

  • Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.

    abstract：BACKGROUND AND OBJECTIVES:The standard of care for HIV treatment is a three-drug regimen consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) and either a non-nucleoside reverse transcriptase inhibitor, a protease inhibitor (PI) or an integrase strand transfer inhibitor. Darunavir boosted with ritonavi...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-016-0456-1

    authors： Lackey P,Mills A,Carpio F,Hsu R,DeJesus E,Pierone G,Henegar C,Fusco J,Fusco G,Wohlfeiler M

    更新日期：2017-01-01 00:00:00

  • Effectiveness and Safety of Amlodipine in Newly Diagnosed Hypertensive Patients and in Previously Diagnosed Hypertensive Patients not Controlled with their Usual Treatment (NOTA Study).

    abstract：OBJECTIVE:To evaluate the effectiveness and safety of amlodipine in two cohorts of hypertensive patients, one newly diagnosed and the other previously diagnosed but not controlled with drug therapy, and to assess the risk factors for the entire sample at the outset of the study. PATIENTS AND DESIGN:We designed a postm...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.2165/00044011-200323120-00001

    authors： Valcárcel Y,Jiménez R,Arístegui R,Gil A,Nota Study Group.

    更新日期：2003-01-01 00:00:00

  • Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study.

    abstract：BACKGROUND AND OBJECTIVES:Currently evidence about clinical and demographic predictors of response to newer antidepressants such as duloxetine is limited. This study aimed to investigate whether a number of predictors, particularly co-morbid anxiety disorders and anxious depression, are associated with clinical improve...

    journal_title：Clinical drug investigation

    pub_type： 临床试验,杂志文章

    doi：10.2165/11588800-000000000-00000

    authors： Nasso ED,Chiesa A,Serretti A,De Ronchi D,Mencacci C

    更新日期：2011-01-01 00:00:00

  • Pharmacoeconomic impact of adverse events of long-term opioid treatment for the management of persistent pain.

    abstract：:Opioids are the most powerful analgesic drugs currently available and consequently form an essential part of the treatment options for malignant and non-malignant chronic pain. However, the benefits of these medications can be offset by gastrointestinal adverse events such as nausea, vomiting and constipation, as well...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章,评审

    doi：10.1007/BF03256935

    authors： Annemans L

    更新日期：2011-01-01 00:00:00

  • Consumption and distribution of propofol in anaesthesia and intensive care use in Finland.

    abstract：BACKGROUND:Propofol is approved both for anaesthesia and sedation during intensive care. Serious adverse reactions with propofol have recently been reported, but patient exposure to the drug is unknown. OBJECTIVE:To investigate the consumption of propofol in Finnish hospitals and to develop a denominator to estimate p...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.2165/00044011-200323010-00003

    authors： Kokki H,Närhi U

    更新日期：2003-01-01 00:00:00

  • The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in Coronary Artery Disease Patients with Type 2 Diabetes Mellitus: Rationale and Design of RosCal Study.

    abstract：INTRODUCTION:More and more evidence suggests that the density of calcification plays an important role in the plaque stability. However, few studies have investigated the statin treatment on the density of plaque calcification in patients with both coronary artery disease (CAD) and type 2 diabetes mellitus. METHODS:On...

    journal_title：Clinical drug investigation

    pub_type： 临床试验,杂志文章

    doi：10.1007/s40261-016-0445-4

    authors： Zhang W,Luan Y,Jin C,Xu S,Bi X,Zhao Y,Qiu F,Fu G,Wang M

    更新日期：2016-12-01 00:00:00

  • Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

    abstract：:Page 806, column 1, line 3: The text, which previously read. ...

    journal_title：Clinical drug investigation

    pub_type： 已发布勘误

    doi：10.1007/s40261-020-00892-9

    authors： Lyseng-Williamson KA

    更新日期：2020-03-01 00:00:00

  • Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.

    abstract：BACKGROUND AND OBJECTIVES:The time-course when changes in glycemic control and body weight were first manifest in patients with type 2 diabetes mellitus (T2DM) treated with a combination of insulin degludec and liraglutide (IDegLira) was assessed, comparing IDegLira to its individual components. METHODS:Data from week...

    journal_title：Clinical drug investigation

    pub_type： 杂志文章

    doi：10.1007/s40261-016-0376-0

    authors： Vilsbøll T,Vora J,Jarlov H,Kvist K,Blonde L

    更新日期：2016-04-01 00:00:00